Cargando…
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic...
Autores principales: | Na, Soo-Young, Choi, Chang Hwan, Song, Eun Mi, Bang, Ki Bae, Park, Sang Hyoung, Kim, Eun Soo, Park, Jae Jun, Keum, Bora, Lee, Chang Kyun, Lee, Bo-In, Ryoo, Seung-Bum, Koh, Seong-Joon, Choi, Miyoung, Kim, Joo Sung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911265/ https://www.ncbi.nlm.nih.gov/pubmed/35645321 http://dx.doi.org/10.5217/ir.2022.00007 |
Ejemplares similares
-
Second Korean guidelines for the management of ulcerative colitis
por: Choi, Chang Hwan, et al.
Publicado: (2017) -
Real-life effectiveness and safety of tofacitinib treatment in
patients with ulcerative colitis: a KASID multicenter cohort
study
por: Shin, Seung Hwan, et al.
Publicado: (2023) -
Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012) -
Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
por: Park, Soo-Kyung, et al.
Publicado: (2022) -
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
por: Koh, Seong-Joon, et al.
Publicado: (2023)